Experimental mRNA vaccines gain steam with promising cancer trial results

Pharmaceutical giants Moderna and Merck announced promising results from a clinical trial testing a combined treatment of an mRNA vaccine and immunotherapy for skin cancer. Melanoma patients who received monthly mRNA vaccines and Merck’s Keytruda immunotherapy had lower chances of cancer recurrence and spread, as well as higher survival rates, than those who received Keytruda alone.